Sign inJoin
Company / Finance

Johnson & Johnson

JNJ · NYSE

Johnson & Johnson reported FY2025 revenue of $94.2 billion, FY2025 net income of $26.8 billion and 2026 Q1 revenue of $24.1 billion. The thesis depends on pharma growth, medtech execution, litigation outcomes and cash conversion.

FollowAdd to WatchlistAsk Question
NYSEJNJCoverage BootstrapJohnson & Johnson
Latest ReportMay 19, 2026Johnson & Johnson: the healthcare compounder has to keep litigation from swallowing the pipelineView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Johnson & Johnson: the healthcare compounder has to keep litigation from swallowing the pipeline

Johnson & Johnson reported FY2025 revenue of $94.2 billion, FY2025 net income of $26.8 billion and 2026 Q1 revenue of $24.1 billion. The thesis depends on pharma growth, medtech execution, litigation outcomes and cash conversion.

May 19, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Johnson & Johnson& Johnson: the healthcare compounder has to keep litigation fromMay 19, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Johnson & Johnson: the healthcare compounder has to keep litigation from swallowing the pipelineJohnson & Johnson reported FY2025 revenue of $94.2 billion, FY2025 net income of $26.8 billion and 2026 Q1 revenue of $24.1 billion. The thesis depends on pharma growth, medtech execution, litigation outcomes and cash conversion.NYSEMay 19, 2026Research reportReadSlides